Abstract:Purpose/Objective(s) Mucosal melanoma of the head and neck is a rare and deadly disease. The optimal treatment for mucosal melanoma remains uncertain, and there is no consensus on the most effective treatment approach, including the extent of surgical resection, the use of adjuvant therapy, and the role of immunotherapy. Current controversies and unknowns about disease treatment and outcomes stem from the rarity of mucosal melanoma, the lack of large-scale clinical trials, and the heterogeneity of the disease. This study aims to determine the survival benefit of immunotherapy, surgery and radiation in setting of mucosal melanoma. Materials/Methods We extracted data from NCDB database with histology codes (ICD-O 2 melanoma codes M872–M879) for patients with mucosal melanoma diagnosed from year 2000-2020 with a total sample size 3937. The patients’ characteristics were summarized by median and interquartile range (IQR) for a continuous variable and by frequency and percentage for a categorical variable. We considered the different combinations of treatments in terms of surgery, chemotherapy, radiation therapy, and immunotherapy. The outcome variables are (1) time to death since diagnosis, and (2) death. Kaplan-Meier survival estimates were used. The log-rank test was employed to compare the survival distributions of the different treatment groups. Cox Proportional Hazard Regression model was performed to evaluate the association between the treatment combinations and survival outcome, adjusting the clinical and demographic variables (e.g., sex, age, stage of cancer). Hazard ratio (HR) and 95% confidence interval (CI) were reported. Mortality rate for each treatment combination was also reported, and the multiple logistic regression model was used to examine the effect of different treatment on mortality. Results The median overall survival (OS) time for all patients diagnosed with mucosal melanoma was 25.7 months. Among them, 50.1% were males, 9.4% younger than 50 years old and 50.6% older than 70, 88.7% white, and 57.6% with Medicare. Cox proportional hazard model showed that the survival time is significantly associated with the following factors: age group 60-70 (HR 1.25, 95%CI [1.06, 1.48]) and >70 (HR 1.83, 95%CI [1.56, 2.13]) comparing with age group <50. Male sex increased the risk of death (HR 1.13, 95%CI[1.04, 1.22]). Surgery decreased the risk of death (HR 0.49, 95%CI [0.44, 0.55]). The use of radiation and immunotherapy had no association with survival. Chemotherapy increased the risk of death (HR 1.33, 95%CI [1.18,1.51]), and was associated with more advanced age and high tumor stage. The multiple logistic regression model showed similar impact of these factors on mortality. Conclusion Treatment paradigms for mucosal melanoma vary widely. Local therapy remains important for improved survival. Further analyses should be done to explore the benefits of multi-modality treatment.

An Evidence-Based Staging System for Mucosal Melanoma: A Proposal

Mucosal Melanoma Staging And Classification: Firstly Established.

Stage-specific prognostic biomarkers in melanoma.

Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients

Multivariate Analysis of Prognostic Factors among 706 Mucosal Melanoma Patients.

Establishment and verification of novel TNM staging system for lung mucinous adenocarcinoma

Assessment of the Novel, Practical, and Prognosis-Relevant TNM Staging System for Stage I-III Cutaneous Melanoma

Development And Validation Of A Surgical-Pathologic Staging And Scoring System For Cervical Cancer

Clinical Presentation, Systemic Therapy and Prognosis of Mucosal Melanoma, A Study of 463 Consecutive Cases

The clinicopathological and survival analysis of urological mucosal melanoma: A single-center retrospective observational study.

[New Clinical Staging System for Carcinoma of Nasal Cavity].

Local Therapy in the Management of Mucosal Melanoma: An NCDB Analysis

Clinical staging of mucosal melanoma of head and neck

Clinical presentation, histology and prognosis of mucosal melanoma in ethnic Chinese: A study of 212 consecutive cases

The Revised Staging System for Malignant Pleural Mesothelioma Based on Surveillance, Epidemiology, and End Results Database

Proposal for the 8th Edition of AJCC/UICC Staging System for Nasopharyngeal Cancer in the Era of Intensity-Modulated Radiotherapy

Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy

Comparison of the TNM9th and 8th editions for localized and locally advanced anal squamous cell carcinoma treated nonsurgically and proposal of a new stage grouping system

New proposed tumor-node-metastasis staging system for medullary thyroid carcinoma based on the Surveillance, Epidemiology, and End Results database.

Clinicopathological Features, Staging Classification, and Clinical Outcomes of Esophageal Melanoma: Evaluation of a Pooled Case Series

A Retrospective Analysis of the Prognostic Factors and Adverse Events in the Treatment of Mucosal Melanoma in a Single Centre